Interim Guidance for the use of Tocilizumab in the Management of Patients who have Severe COVID-19 with Suspected Hyperinflammation [v5.0]
Authors
Bergin, C.Browne, P.
Murray, P.
O'Dwyer, M.
Conlon, N.
Kane, D.
Laffey, John
Ní Choitir, C.
Adams, R.
O'Leary, A.
King, F.
Gilvarry, P.
Issue Date
2020-09-02Keywords
CORONAVIRUSCOVID-19
HYPERINFLAMMATION
DRUG THERAPY